These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32716062)

  • 1. Isolated echogenic intracardiac foci and the role of cell-free fetal DNA: A cost-effectiveness analysis.
    Hacker FM; Hersh AR; Shaffer BL; Caughey AB
    Prenat Diagn; 2020 Dec; 40(12):1517-1524. PubMed ID: 32716062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-free fetal DNA screening for detection of microdeletion syndromes: a cost-effectiveness analysis.
    Avram CM; Shaffer BL; Sparks TN; Allen AJ; Caughey AB
    J Matern Fetal Neonatal Med; 2021 Jun; 34(11):1732-1740. PubMed ID: 31327283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of ultrasound before non-invasive prenatal screening for fetal aneuploidy.
    Battarbee AN; Vora NL; Hardisty EE; Stamilio DM
    Ultrasound Obstet Gynecol; 2023 Mar; 61(3):325-332. PubMed ID: 36273429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free DNA for Down syndrome screening in obese women: Is it a cost-effective strategy?
    Hopkins MK; Dugoff L; Durnwald C; Havrilesky LJ; Dotters-Katz S
    Prenat Diagn; 2020 Jan; 40(2):173-178. PubMed ID: 31803969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echogenic intracardiac foci: associated with increased risk for fetal trisomy 21 or not?
    Shanks AL; Odibo AO; Gray DL
    J Ultrasound Med; 2009 Dec; 28(12):1639-43. PubMed ID: 19933476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China.
    Xu Y; Wei Y; Ming J; Li N; Xu N; Pong RW; Chen Y
    Int J Technol Assess Health Care; 2019 Jan; 35(3):237-242. PubMed ID: 31131776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies.
    Huang T; Gibbons C; Rashid S; Priston MK; Bedford HM; Mak-Tam E; Meschino WS
    BMC Pregnancy Childbirth; 2020 Nov; 20(1):713. PubMed ID: 33228595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-trimester screening based on cell-free DNA vs combined screening: A randomized clinical trial on women's experience.
    Migliorini S; Saccone G; Silvestro F; Massaro G; Arduino B; D'Alessandro P; Petti MT; Paino JAC; Guida M; Locci M; Zullo F
    Prenat Diagn; 2020 Oct; 40(11):1482-1488. PubMed ID: 32683755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the use of the isolated echogenic intracardiac focus as a screen for Down syndrome in women under the age of 35 years.
    Caughey AB; Lyell DJ; Filly RA; Washington AE; Norton ME
    Am J Obstet Gynecol; 2001 Nov; 185(5):1021-7. PubMed ID: 11717625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of five prenatal screening strategies for trisomies and other unbalanced chromosomal abnormalities: model-based analysis.
    Le Bras A; Salomon LJ; Bussières L; Malan V; Elie C; Mahallati H; Ville Y; Vekemans M; Durand-Zaleski I
    Ultrasound Obstet Gynecol; 2019 Nov; 54(5):596-603. PubMed ID: 31006923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis.
    Fairbrother G; Burigo J; Sharon T; Song K
    J Matern Fetal Neonatal Med; 2016; 29(7):1160-4. PubMed ID: 26000626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An isolated intracardiac echogenic focus as a marker for aneuploidy.
    Bradley KE; Santulli TS; Gregory KD; Herbert W; Carlson DE; Platt LD
    Am J Obstet Gynecol; 2005 Jun; 192(6):2021-6; discussion 2026-8. PubMed ID: 15970883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis.
    Nshimyumukiza L; Beaumont JA; Duplantie J; Langlois S; Little J; Audibert F; McCabe C; Gekas J; Giguère Y; Gagné C; Reinharz D; Rousseau F
    J Obstet Gynaecol Can; 2018 Jan; 40(1):48-60. PubMed ID: 28784564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free DNA and contingent screening: Our first year.
    Gomes HH; Lourenço I; Ribeiro J; Martins D; Ribeiro R; Francisco C
    J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):509-514. PubMed ID: 30951890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of validity of echogenic intracardiac foci for calculating the risk of Down syndrome in the second trimester of pregnancy.
    Lorente AMR; Moreno-Cid M; Rodríguez MJ; Bueno G; Tenías JM; Román C; Arias Á; Pascual A
    Taiwan J Obstet Gynecol; 2017 Feb; 56(1):16-22. PubMed ID: 28254219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness Analysis.
    Xie X; Wang M; Goh ES; Ungar WJ; Little J; Carroll JC; Okun N; Huang T; Rousseau F; Dougan SD; Tu HA; Higgins C; Holubowich C; Sikich N; Dhalla IA; Ng V
    J Obstet Gynaecol Can; 2020 Jun; 42(6):740-749.e12. PubMed ID: 32008974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.
    Zhang W; Mohammadi T; Sou J; Anis AH
    PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective?
    Bak GS; Shaffer BL; Madriago E; Allen A; Kelly B; Caughey AB; Pereira L
    Ultrasound Obstet Gynecol; 2020 Nov; 56(5):705-716. PubMed ID: 31614030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis comparing two different strategies in advanced maternal age: Combined first-trimester screening and maternal blood cell-free DNA testing.
    Pan M; Huang LY; Zhen L; Li DZ
    Taiwan J Obstet Gynecol; 2018 Aug; 57(4):536-540. PubMed ID: 30122574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.